Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 83, Issue 3, Pages 237-244Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2015.06.024
Keywords
MALDI-TOF MS; ESBL-producing Escherichia coli; B2-ST131; Proteomic analysis; Genomic analysis; YahO protein
Categories
Funding
- JSPS KAKENHI [25860469]
- Grants-in-Aid for Scientific Research [25860469] Funding Source: KAKEN
Ask authors/readers for more resources
One reason for the spread of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli worldwide is the global pandemic of the B2-ST131 clonal group. We searched for the specific biomarker peaks to distinguish between the B2-ST131 clonal group and other sequence type (ST) clonal groups isolated from clinical specimens obtained in our hospital. Biomarker peaks at m/z 7650 in the B2-ST131 group (sensitivity of 100% and specificity of 89.7%) and m/z 7707 in the other ST clonal groups showed the highest discrimination abilities. We further verified reproducibility against other Japanese clinical isolates obtained in another area of Japan. Differences between the molecular mass at the 7650 m/z and 7707 m/z peaks indicated an E34A amino acid substitution by proteomic and genomic analysis. Matrix-assisted laser desorption ionization-time-of-flight mass spectrometry rapidly and simply identified the B2-ST131 clonal group in routine examinations and will allow for adequate empirical therapy and the possibility to control both hospital infections and the global pandemic. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available